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Background/aim: The aim of the study was to investigate whether treating haematological malignancy (HM) patients in a separate
intensive care unit (ICU) would reduce ICU mortality.
Materials and methods: HM patients treated by the same ICU team in a general medical ICU (GM-ICU) and a separate haematology
ICU (H-ICU) were included in this study. Patients’ demographic characteristics and ICU data were recorded retrospectively. Differences
in the ICU course and prognosis between these two groups were determined.
Results: A total of 251 patients (102 from GM-ICU, 149 from H-ICU) were included in this study. The disease severity and organ failure
scores at ICU admission and underlying HMs were not different between the two groups. Patients waited longer for admission to GMICU. Therapeutic procedures were performed significantly more frequently in GM-ICU. ICU complications were not different between
the groups. ICU mortality rates were higher in GM-ICU (59.8% vs 37.6%, p = 0.006).
Conclusion: A separate ICU allocated for haematology patients will allow timely and rapid admission of HM patients to ICU. Thus,
mortality rates of HM patients needing ICU care will decline.
Key words: Intensive care unit, separate intensive care unit, patients with haematological malignancies, intensive care unit mortality

1. Introduction
Intensive care units (ICUs) should have a rational triage
system for patient admission because of the limited ICU
bed capacity. The high ICU mortality rate and ambiguity
concerning the effects of life or organ support in critical
cancer patients, especially patients with haematological
malignancies (HMs), lead to the development of passive
resistance to admitting such patients in ICUs [1–3].
The presence of a separate ICU for critically-ill
cancer patients, especially critically-ill HM patients,
eliminates the triage steps for the admission of such
patients; ensuring avoiding the competition for the same
bed across patients with different diseases and enables
critically-ill HM patients to get ICU support timely and
rapidly. Implementation of a separate ICU for criticallyill cancer patients, especially critically-ill HM patients
will contribute to the accumulation of knowledge and
experience further in this special patient group and
promote early interventions for some specific situations
that might remain unnoticed in a general ICU resulting in
decreases in morbidity and mortality.

In this study, we compared HM patients treated in a
separate haematology ICU (H-ICU) with HM patients
treated in a general medical ICU (GM-ICU) to show
whether there were differences in the ICU course and
mortality between these two groups of patients during the
ICU stay.
2. Materials and methods
Gazi University Hospital is a tertiary referral hospital
with approximately 1000 beds in the city of Ankara. In
the hospital, there is a 35-bed haematology clinic and an
8-bed bone marrow transplant unit. Because of delays in
admissions to GM-ICU, a 4-bed tertiary ICU (H-ICU)
was established in the hospital in 2014 for critically-ill
haematology patients. Another aim to establish a separate
H-ICU was to avoid treating such immunocompromised
patients in the same unit where patients with other
types of diseases are treated, too. The organizational and
administrative tasks of the newly established H-ICU were
assigned to the ICU team experienced in the follow-up and
treatment of HM patients in the GM-ICU. Currently, an
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internal medicine physician is available in the H-ICU for
7 days and 24 h, and an ICU specialist is available during
working hours. In the newly established H-ICU, 100-120
patients receive treatment in a year. Patients admitted to
H-ICU are usually composed of HM patients.
We planned this retrospective study to determine
whether treating critically-ill HM patients in a separate
H-ICU acted on ICU mortality rates. The study included
HM patients treated in the GM-ICU within the 2 years (in
the period between January 01, 2012 and December 31,
2013) before the establishment of H-ICU and included
HM patients treated in the H-ICU within the 2 years
after its establishment (in the period between January 01,
2014 and December 31, 2015). Patients who stayed in the
ICU longer than 24 h and first admission of the patients
who were admitted to the ICU more than once were
included in this study. In addition to the demographic
characteristics of the patients, the following data for
each patient were recorded including the characteristics
referral information for the ICU admission (from where,
when, why, etc), co-morbidities, type of HM, disease
status (new diagnosis, under control, relapse, end-stage
etc.), vital signs at admission, acute disease severity and
organ failure scores (acute physiology and chronic health
evaluation - APACHE II score, sequential organ failure
assessment - SOFA score, Glasgow coma scale - GCS etc. )
at admission, laboratory values at admission, therapeutic
procedures that the patient underwent during the ICU
stay (mechanical ventilation – MV, renal replacement
therapy – RRT, etc.), existing infections at ICU admission,
infections and complications (gastrointestinal - GI
bleeding, sepsis, acute kidney injury – AKI, etc.) during
the ICU stay, and ICU outcomes (survival or death ).
Then, the data of critically-ill HM patients treated in
GM-ICU were compared with those of critically-ill HM
patients treated in H-ICU to find out whether there were
differences between these two groups, especially in terms
of ICU course and outcomes.
2.1. Statistical analysis
Statistical analysis was performed using the IBM SPSS
(Statistical Package for Social Sciences) statistical
software package version 22.0 (IBM Corp., Armonk,
NY, USA). Continuous variables were reported as
mean ± standard deviations or median [interquartile
ranges]. Frequencies and percentages were used for
the presentation of categorical variables. Patients were
divided into two groups as HM patients treated in GMICU and HM patients treated in H-ICU. The Mann–
Whitney U test or Student’s t-test was used to compare
continuous variables, the chi-square test or Fisher’s exact
test was used to compare categorical variables. P values
lower than 0.05 were considered statistically significant.
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3. Results
A total of 251 patients were included in the study. The
numbers of critically-ill HM patients treated in GMICU and H-ICU were 102 and 149, respectively. No
statistically significant differences were observed between
the two groups in APACHE II, SOFA, and GCS scores at
ICU admission, the length of ICU stay, sex distribution,
underlying haematological malignancies, disease status, the
status and type of haematopoetic stem cell transplantation
(HSCT) (Table 1). While patients admitted to H-ICU were
older, end-stage cancer and comorbidities in this patient
group were more frequent; patients admitted to GMICU waited longer for ICU admission and suffered from
respiratory failure more frequently at the time of ICU
admission (Table 1).
There were no differences in vital signs between the two
groups at ICU admission but haemoglobin, procalcitonin,
sodium, and LDH levels were significantly different
between the two groups at the time of ICU admission
(Table 2). Pulmonary sepsis as a cause of ICU admission
was more common in patients admitted to GM-ICU
(Table 2). Invasive mechanical ventilation support was
more common in GM-ICU patients at ICU admission. As
for diagnostic and therapeutic procedures performed in
ICU, invasive mechanical ventilation (IMV) support and
arterial catheterization were significantly more commonly
performed in GM-ICU (Table 2). The development
of complications (GI bleeding, AKI, arrhythmias,
nosocomial infections, etc.) during the ICU stay were not
different between the groups (Table 2). The comparison
of the groups for mortality in ICU revealed that 63.7%
of the patients treated in GM-ICU died, and 49% of the
patients treated in H-ICU died. The difference between
the groups was statistically significant (p = 0.021) (Table
2). When end-stage HM patients were excluded from both
groups, the net ICU mortality rate was 59.8% in GM-ICU
patients, and 37.6% in H-ICU patients. The difference in
ICU mortality rates was statistically significant between
the two groups (p = 0.006) (Table 2).
4. Discussion
Haematological malignancy patients require frequently
ICU admissions due to comorbidities, primary disease,
and treatment-associated side effects. But for years, the
ICU admission of HM patients has created an ethical
dilemma because of poor prognosis and high mortality
rates in this patient group during their stay in ICU.
Despite the developments in cancer treatment and organ
support therapies enabling this patient group to achieve
better prognostic outcomes over the last 20–30 years [1–
4], ICU mortality is still high (30%–80%) [2,5–8]. In this
retrospective study, we showed that outcome and prognosis
of HM patients who required ICU care were better if treated
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Table 1. General characteristics of all study patients, and patients in haematology ICU and general medical ICU.
Parameter

All study patients
(n = 251)

Patients in haematology ICU Patients in general
P value
(n = 149)
medical ICU (n = 102)

Age*

58 [47–66]

59 [49.5–66.5]

56 [42.75–64.25]

0.035

Admission APACHE II score*

23 [19–29]

23 [19–28.5]

23 [18–29]

0.78

Admission GCS*

14 [9–15]

14 [9–15]

13 [9–15]

0.212

Admission SOFA score*

8 [6–12]

8 [5–11]

9 [6–12]

0.352

Length of ICU stay* (days)

6 [3–13]

6 [3–15]

6.5 [4–12]

0.969

Waiting time for ICU admission* (hours)

8 [4–16]

5 [3–9]

16 [8–22.5]

0.0001

Sex, M, n (%)

161 (63.9)

94 (63.1)

67 (65.7)

0.673

113 (44.8)
76 (30.2)
68 (27)

68 (45.6)
47 (31.5)
37 (24.8)

45 (44.1)
29 (28.4)
31 (30.4)

0.812
0.598
0.330

88 (34.9)
94 (37.3)
40 (15.9)
21 (8.3)

48 (32.2)
52 (34.9)
25 (16.8)
17 (11.4)

40 (39.2)
42 (41.2)
15 (14.7)
4 (3.9)

0.659
0.313
0.659
0.035

54 (21.4)
45 (17.9)

28 (18.8)
28 (18.8)

26 (25.5)
17 (16.7)

0.205
0.666

56 (22.2)
53 (21)
47 (18.7)
28 (11.1)

44 (29.5)
40 (26.8)
31 (20.8)
20 (13.4)

12 (11.8)
13 (12.7)
16 (15.7)
8 (7.8)

0.001
0.007
0.307
0.168

192 (76.2)
180 (71.4)
78 (31)
62 (24.6)

111 (74.5)
99 (66.4)
40 (26.8)
39 (26.2)

81 (79.4)
81 (79.4)
38 (37.3)
23 (22.5)

0.367
0.025
0.08
0.513

Underlying hematologic malignancies, n (%)
Acute Leukemia
Multiple Myeloma
Lymphoma
Status of hematological malignancy, n (%)
Recently-diagnosed
Relapsed
In remission
End-stage
HSCT, n (%)
Allogeneic
Autologous
Co-morbidities, n (%)
Diabetes Mellitus
Chronic heart diseases
Chronic renal diseases
Chronic lung diseases
Reasons for ICU admission, n (%)
Sepsis/septic shock
Respiratory failure
Renal failure
Change in consciousness

* median [interquartile ranges], n: number
ICU: intensive care unit, APACHE: acute physiology and chronic health evaluation, GCS: Glasgow coma scale, SOFA: sequential organ
failure assessment, M: male, HSCT: hematopoietic stem cell transplantation.

in its own ICU as in new study by Kalicińska et al [8]. We
found that ICU mortality rate of HM patients treated in a
separate and private ICU, namely H-ICU, was significantly
lower than that of HM patients treated in GM-ICU in spite
of similar haematological disease characteristics, disease
severity and organ failure scores (49% vs 63.7%, p = 0.021).
Moreover, when one considered the higher number of
end-stage HM patients in H-ICU, the difference between
mortality rates of GM-ICU and H-ICU became even more
striking (37.6% vs 59.8%, p = 0.006).
As HM patients are considered to have a poor
prognosis, ICU admission is not prioritized for these

patients in triage system. However, instead of considering
all these patients as the same, it may be more prudent
to perform a customized evaluation for each patient. In
some studies, it has been reported that some factors at
ICU admission or during the ICU stay determine the ICU
prognosis. These factors include type and the status of HM
at ICU admission, age, presence or absence of alternative
treatment options for HM, neutropenia, presence and type
of HSCT procedure, graft versus host disease (GVHD),
severity of the acute disease, requirement of IMV support,
need of vasopressor and inotrope for hemodynamic
stability, presence of sepsis, invasive fungal infections,
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Table 2. ICU admission and follow-up characteristics of all study, haematology ICU and general medical ICU patients included in the
study.
Parameter

All study patients Patients in haematology Patients in general
P
(n = 251)
ICU (n = 149)
medical ICU (n = 102) value

Vital signs at ICU admission*
Body temperature (°C)
Pulse ( /min)
Mean arterial pressure (mmHg)
Respiratory rate (/min)

36.7 [36.4–37.1]
119 [102.5–131]
72 [62–84.5]
28 [23–32]

36.7 [36.4–37]
119 [104–132]
71 [62–84]
28 [24–34]

36.7 [36.3–37.28]
117 [102–130]
74 [62.25–85.75]
26 [22–32]

0.995
0.714
0.256
0.136

8 [7.18–9.2]
4400 [800–10490]
98 (38.9)
2.95 [0.7–19.8]
1.15 [0.67–2.22]
137 [133–141]
20 [12–39]
378 [268–720]
2.6 [2.2–3]

7.8 [6.7–8.88]
3994 [515–9104]
63 (42.3)
1.89 [0.4–9.64]
1.09 [0.6–1.86]
136 [133–140]
20 [12–42]
353 [245–672]
2.63 [2.2–3.03]

8.47 [7.40–9.7]
4775 [1510–11315]
35 (34.3)
6.74 [1.85–31]
1.19 [0.7–2.44]
138 [135–143]
21 [12–36.25]
472.5 [312.3–859.8]
2.6 [2.3–3]

0.002
0.128
0.398
0.0001
0.146
0.05
0.771
0.006
0.885

Pulmonary
Bloodstream/catheter related bloodstream
Abdominal
Urinary

156 (61.9)
44 (17.5)
34 (13.5)
24 (9.5)

84 (56.4)
27 (18.1)
17 (11.4)
10 (6.7)

72 (70.6)
17 (16.7)
17 (16.7)
14 (13.7)

0.023
0.766
0.232
0.063

IMV support at ICU admission, n (%)

63 (25)

30 (20.1)

33 (32.4)

0.045

Vasopressor support at ICU admission, n (%)

84 (33.3)

47 (31.5)

37 (36.3)

0.372

112 (44.4)
161 (63.9)
193 (76.6)
189 (75)
65 (25.8)

63 (42.3)
86 (57.7)
104 (69.8)
107 (71.8)
42 (28.2)

49 (48)
75 (73.5)
89 (87.3)
82 (80.4)
23 (22.5)

0.367
0.01
0.001
0.122
0.317

Nosocomial infections
AKI
Cardiac
GI bleeding
Pneumothorax

80 (31.7)
83 (32.9)
25 (9.9)
22 (8.7)
11 (4.4)

51 (34.2)
45 (30.2)
17 (11.4)
15 (10.1)
8 (5.4)

29 (28.4)
38 (37.3)
8 (7.8)
7 (6.9)
3 (2.9)

0.333
0.243
0.354
0.378
0.533

Crude ICU mortality rate, n (%)

138 (54.8)

73 (49)

65 (63.7)

0.021

Net ICU mortality rate, n (%) **

117 (46.6)

56 (37.6)

61 (59.8)

0.006

Some laboratory parameters at ICU admission
Hemoglobin* (g/dL)
White blood cell* (/mm 3)
Neutropenia, n (%)
Procalcitonin* (ng/mL)
Creatinine* (mg/dL)
Sodium* (mEq/L)
ALT* (U/L)
LDH* (U/L)
Albumin* (g/dL)
Origin of sepsis at ICU admission, n (%)

Procedures performed during ICU stay, n (%)
NIV
IMV
Arterial catheterization
Central venous catheterization
RRT
Complications developed during ICU stay, n (%)

* median [interquartile range], n: number,
ICU: intensive care unit, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, IMV: invasive mechanical ventilation, NIV:
noninvasive mechanical ventilation, RRT: renal replacement therapy, AKI: acute kidney injury, GI: gastrointestinal.
** Net mortality rate is the mortality rate calculated by subtracting the number of end-stage HM patients from the number of HM
patients who died.

severe comorbidities and multiple organ failures, and
need of organ support therapies [9–18]. Determining
the factors affecting the prognosis of HM patients was
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beyond the scope of this study. However, we observed
that the ICU mortality rate was high in HM patients who
experienced a long waiting time until ICU admission,
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who were admitted to ICU due to respiratory failure and
pulmonary sepsis, who had higher procalcitonin, sodium,
and lactate dehydrogenase levels at the ICU admission,
and who required more invasive arterial monitoring and
IMV support during the ICU stay. All of these findings
suggested that the admission of HM patients to our GMICU was delayed. The increase in survival of HM patients
who need ICU care, can only be achieved by eliminating
the prejudice existing for these patients in the ICU triage
system or by establishing special ICUs for these patients.
Early detection of haemodynamic and respiratory
deteriorations and rapid initiation of necessary treatments
before the development of multiple organ failures
are important for prognosis in HM patients [11–13].
Therefore, patients need to be transferred to ICUs swiftly.
In ICUs accepting patients, regardless of the diagnosis,
early ICU admission of HM patients is often hardly
possible because of the high number of patients on the
waiting list and because HM patients are not prioritized
in the ICU triage system. Indeed, our patients, too, were
admitted to our GM-ICU after a long waiting period. This
delay may explain the high mortality rate in this patient
group in our study. Again, HM patients were admitted to
our GM-ICU mostly due to respiratory failure and they
needed IMV support more. However, if these patients had
been admitted to the ICU earlier, they could have received
early non-invasive mechanical ventilation (NIV) support
or high flow nasal oxygen (HFNO) therapy rather than
receiving IMV support, and they could have recovered
better and mortality could have been lower. Achieving such
favourable outcomes can only be made possible through
the establishment of specialized ICUs admitting only these
patients. The establishment of specialized ICUs for these
patients may allow to find the chance for early admission
not only for the treatment of respiratory failure but also for
the monitorization of hemodynamic parameters and for
the management of metabolic disorders and sepsis.
It is known that prognosis is better in cancer
patients treated in a specialized ICU or a specialized
centre compared to cancer patients treated in a general
ICU or a centre admitting patients with any diagnosis.
Specialization of a unit or centre results in monitoring
and treating a large number of patients having the same
diagnosis, leading to accumulating experience and
knowledge on the specialized subject. This, in turn, will
enable the utilization of specialized experience and
knowledge in the treatment of patients [19]. This is a
subject matter, which has been previously proven by

Kahn et al. and by Shahin et al. in studies on mechanically
ventilated patients [20,21]. Again, monitoring a large
number of patients with a specific diagnosis can enable to
establish a better organizational structure, develop clearer
protocols, build multidisciplinary teams, and perform
better staffing in a given centre. Reduced mortality in the
presence of an increased number of cases (case-volume)
was demonstrated previously in haematological patients
by Lecuyer et al. and by Hampshire et al. [19,22].
In our study, end-stage HM patients were more frequent
in the H-ICU. This may be due to two reasons. The first
one is that the haematologist and ICU specialist could not
reach a consensus on the prognosis of the patient and they
considered to make a decision by following the patient in
ICU. The second one is that H-ICU has been established as
a specialized unit to treat only HM patients, but it turned
out to serve as a palliative care unit, too. However, in the
latter case, it may be hard to benefit from H-ICU for both
purposes because of the inadequate bed capacity and the
team’s lack of knowledge on palliative care.
Our study has some limitations. Firstly, our study
is retrospective. There may be data loss in retrospective
studies. Secondly, it is a single center study meaning that
the results of the study cannot be generalized because
of the use of local protocols and approaches for ICU
admission, discharges, procedures in patient care, and
treatment. Thirdly, it is necessary to demonstrate longterm results and the quality of life after patients are
discharged from H-ICU. Lastly, it is required to determine
the cost-effectivity of the establishment of this specialized
H-ICU and giving patient care in such a unit.
In conclusion, the availability of a separate haematology
intensive care unit enabled haematological malignancy
patients to have access to intensive care in a timely
manner. This decreased the ICU mortality rates of patients
with haematological malignancies. However, multicentre,
large-scale studies are needed to confirm our results and
demonstrate the effects of such specialized units on longterm survival and the quality of life.
Acknowledgment/Disclaimers/Conflict of interest
The authors declare that they have no conflicts of interest.
No financial support or grant was received for this study.
Informed consent
This study was approved by the Ethics Committee of
Keçiören Training and Research Hospital (date: June 24,
2015 and number: 886).

2099

AYGENCEL et al. / Turk J Med Sci
References
1.

Thiéry G, Azoulay E, Darmon M, Ciroldi M, De Miranda S
et al. Outcome of cancer patients considered for intensive care
unit admission: a hospital-wide prospective study. Journal of
Clinical Oncology 2005; 23 (19): 4406-4413. doi: 10.1200/
JCO.2005.01.487

2.

Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M.
Prognostic factors in critically ill cancer patients admitted to
the intensive care unit. Journal of Critical Care 2014; 29 (4):
618-626. doi:10.1016/j.jcrc.2014.01.014

3.

Soares M, Caruso P, Silva E, Teles JM, Lobo SM et al.
Brazilian Research in Intensive Care Network (BRICNet).
Characteristics and outcomes of patients with cancer requiring
admission to intensive care units: a prospective multicenter
study. Critical Care Medicine 2010; 38 (1): 9-15. doi: 10.1097/
CCM.0b013e3181c0349e

4.

Cherif H, Martling CR, Hansen J, Kalin M, Björkholm M.
Predictors of short and long-term outcome in patients with
hematological disorders admitted to the intensive care unit
for a life-threatening complication. Supportive Care in Cancer
2007; 15 (12): 1393-1398. doi: 10.1007/s00520-007-0268-1

5.

Namendys-Silva SA, González-Herrera MO, García-Guillén
FJ, Texcocano-Becerra J, Herrera-Gómez A. Outcome of
critically ill patients with hematological malignancies. Annals
of Hematology 2013; 92 (5): 699-705. doi: 10.1007/s00277-0131675-7

6.

Magid T, Haase N, Andersen JS, Nielsen OJ, Bonde J. Intensive
care of haematological patients. Danish Medical Journal 2012;
59 (3): A4395. PMID: 22381090

7.

Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber
PC. Outcomes and prognostic factors in patients with
haematological malignancy admitted to a specialist cancer
intensive care unit: a 5 yr study. British Journal of Anaesthesia
2012; 108 (3): 452-459. doi: 10.1093/bja/aer449

8.

Kalicińska, E, Kuszczak, B, Dębski J, Szukalski L, Wątek M et
al. Hematological malignancies in Polish population: what are
the predictors of outcome in patients admitted to Intensive
Care Unit? Supportive Care in Cancer 2021; 29: 323-330. doi:
10.1007/s00520-020-05480-3

9.

Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y et al.
Characteristics and outcomes of cancer patients in European
ICUs. Critical Care 2009; 13 (1): R15. doi: 10.1186/cc7713

10.

Gordon AC, Oakervee HE, Kaya B, Thomas JM, Barnett
MJ et al. Incidence and outcome of critical illness amongst
hospitalised patients with haematological malignancy: a
prospective observational study of ward and intensive care
unit based care. Anaesthesia 2005; 60 (4): 340-347. doi:
10.1111/j.1365-2044.2005.04139.x

11.

Hampshire PA, Welch CA, McCrossan LA, Francis K, Harrison
DA. Admission factors associated with hospital mortality in
patients with haematological malignancy admitted to UK
adult, general critical care units: a secondary analysis of the
ICNARC Case Mix Programme Database. Critical Care 2009;
13 (4): R137. doi: 10.1186/cc8016

2100

12.

Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A et
al. Outcomes of critically ill patients with hematologic
malignancies: prospective multicenter data from France and
Belgium--a groupe de recherche respiratoire en réanimation
onco-hématologique study. Journal of Clinical Oncology 2013;
31 (22): 2810-2818. doi: 10.1200/JCO.2012. 47.2365

13.

Azoulay E, Pène F, Darmon M, Lengliné E, Benoit D et al.
Groupe de Recherche Respiratoire en Réanimation OncoHématologique (Grrr-OH). Managing critically ill hematology
patients: Time to think differently. Blood Reviews 2015; 29 (6):
359-367. doi: 10.1016/j.blre.2015.04.002

14.

Hill QA, Kelly RJ, Patalappa C, Whittle AM, Scally AJ et al.
Survival of patients with hematological malignancy admitted
to the intensive care unit: prognostic factors and outcome
compared to unselected medical intensive care unit admissions,
a parallel group study. Leukemia & Lymphoma. 2012; 53 (2):
282-288. doi: 10.3109/10428194. 2011.614705

15.

Yeo CD, Kim JW, Kim SC, Kim YK, Kim KH et al. Prognostic
factors in critically ill patients with hematologic malignancies
admitted to the intensive care unit. Journal of Critical Care
2012; 27 (6): 739.e1-6. doi: 10.1016/j.jcrc.2012.07.014

16.

Ferrà C, Marcos P, Misis M, Morgades M, Bordejé ML et al.
Outcome and prognostic factors in patients with hematologic
malignancies admitted to the intensive care unit: a singlecenter experience. International Journal of Hematology 2007;
85 (3): 195-202. doi: 10.1532/IJH97.E0625

17.

Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA,
Colardyn FA. Outcome and early prognostic indicators in
patients with a hematologic malignancy admitted to the
intensive care unit for a life-threatening complication. Critical
Care Medicine 2003; 31 (1): 104-112. doi: 10.1097/00003246200301000-00017

18.

Al-Zubaidi N, Shehada E, Alshabani K, ZazaDitYafawi
J, Kingah P et al. Predictors of outcome in patients with
hematologic malignancies admitted to the intensive care unit.
Hematology/Oncology and Stem Cell Therapy 2018; 11 (4):
206-218. doi: 10.1016/j.hemonc.2018.03.003

19.

Hampshire PA, Pugh R, Hajimichael P. Outcomes for critically
ill patients with haematological malignancies in specialist
and non-specialist centres in the United Kingdom. Journal of
Cancer Therapeutics & Research 2014; 3: 5. doi: 10.7243/20497962-3-5

20.

Kahn JM, Goss CH, Heagerty PJ, Kramer AA, O’Brien CR et al.
Hospital volume and the outcomes of mechanical ventilation.
New England Journal of Medicine 2006; 355 (1): 41-50. doi:
10.1056/NEJMsa053993

21.

Shahin J, Harrison DA, Rowan KM. Is the volume of
mechanically ventilated admissions to UK critical care units
associated with improved outcomes? Intensive Care Medicine
2014; 40 (3): 353-360. doi: 10.1007/s00134-013-3205-4

22.

Lecuyer L, Chevret S, Guidet B, Aegerter P, Martel P et al. Case
volume and mortality in haematological patients with acute
respiratory failure. European Respiratory Journal 2008; 32 (3):
748-754. doi: 10.1183/09031936.00142907

